KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer.

Yann Christinat, Intidhar Labidi-Galy, Liza Ho, Sophie Clément, Catherine Genestie, Jalid Sehouli, Saverio Cinieri, Antonio Gonzalez-Martin, Vassiliki Kolovetsiou-Kreiner, Keiichi Fujiwara, Toon Von Gorp, Germana Tognon, Sakari Hietanen, Viola Heinzelmann-Schwarz, Isabelle Ray-Coquard, Eric Pujade-Lauraine, Thomas A McKee

JCO Precis Oncol 9 e2400825

PMID40601896
PMCIDPMC12233177
DOI10.1200/PO-24-00825
发表日期2025-07-02
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

PURPOSE: The ability of the Geneva homologous recombination deficiency (HRD) test to predict progression-free survival (PFS) in patients with high-grade ovarian cancer treated with poly (ADP-ribose) polymerase inhibitors has been demonstrated. Its performance with respect to overall survival (OS) has not been assessed yet. METHODS: Using the final results of the PAOLA-1/ENGOT-ov25 phase III clinical trial with a median follow-up of 5 years, we evaluated the Geneva HRD test on 468 samples as part of the ENGOT HRD European Initiative. Results were evaluated in terms of final PFS and OS in the olaparib + bevacizumab and placebo + bevacizumab arms and compared with the Myriad MyChoice HRD test. RESULTS: Final PFS was consistent with previously published data and confirmed the predictive value of the Geneva HRD test with a hazard ratio (HR) of 0.41 (95% CI, 0.30 to 0.57) for HRD-positive patients. The results for OS showed a HR of 0.56 (95% CI, 0.37 to 0.85) for HRD-positive patients and 1.6 (95% CI, 1.1 to 2.3) for HRD-negative patients. These results are consistent with those observed with the Myriad test, including the negative OS trend in the HRD-negative subgroup treated with olaparib + bevacizumab (HR, 1.2 [95% CI, 0.83 to 1.8]). A subgroup analysis of patients with intermediate HRD scores showed that the normalized large-scale state transition score used by the Geneva HRD test had both predictive and prognostic value. CONCLUSION: The Geneva HRD test predicts PFS and OS benefit from olaparib + bevacizumab. The potential detrimental effect of olaparib + bevacizumab on OS in the HRD-negative population is hypothesis-generating and needs to be confirmed prospectively.

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure2 个面板

FIG 4.

PFS and OS in the placebo + bevacizumab arm with respect to the nLST score divided in three categories (HRD-negative: nLST <15; HRD-positive–mid: 15 ≤ nLST < 20; HRD-positive–high: nLST ≥20). (A) PFS and (B) OS. HRD, homologous recombination deficiency; nLST, normalized large-scale state transition; OS, overall survival; PFS, progression-free survival.

A

Progression-Free Survival

FIG 4. · Panel A

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel A 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:short span
查看结果
B

Overall Survival

FIG 4. · Panel B

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel B 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:extreme upward reversal
查看结果
KM Figure2 个面板

FIG A1.

Kaplan-Meier OS curves for the HRD-positive subpopulation, according to the Geneva HRD test, with respect to the BRCA mutation status (given by the Myriad test). (A) BRCA mutated and (B) BRCA wild-type. HR, hazard ratio; HRD, homologous recombination deficiency; OS, overall survival.

A

OS

FIG A1. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG A1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

FIG A1. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG A1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:short span
查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.HR with the updated PFS for (A) the entire cohort (N = 468) and (B) BRCA wild-type tumors (n = 310). The dotted lines with the empty squares represent the data previously reported. GIS, genomic instability score; HR, hazard ratio; nLST, normalized large-scale state transition; PFS, progression-free survival.
非 KM Figure
FIG 2.OS with respect to HRD test. Kaplan-Meier OS curves for (A) HRD-positive and (B) HRD-negative subpopulation by the Geneva HRD test with respect to the treatment arm. (C) HR of OS according to HRD test results (Geneva test and Myriad MyChoice). GIS, genomic instability score; HR, hazard ratio; HRD, homologous recombination deficiency; nLST, normalized large-scale state transition; OS, overall survival.
非 KM Figure
FIG 3.Predictive value (hazard of ratio of olaparib + bevacizumab v placebo + bevacizumab) of the Geneva HRD test on PFS and OS according to the three categories of nLST score (HRD-negative: nLST <15; HRD-positive–mid: 15 ≤ nLST < 20; HRD-positive–high: nLST ≥20). HRD, homologous recombination deficiency; nLST, normalized large-scale state transition; OS, overall survival; PFS, progression-free survival.
非 KM Figure
FIG A2.PFS and OS with respect to the treatment arm, subdivided by the nLST amplitude (negative: <15; positive-mid: 15 ≤ nLST < 20; positive-high: nLST ≥20) and the BRCA mutational status (given by the Myriad test). (A) PFS on BRCA -mutated patients, (B) OS on BRCA -mutated patients, (C) PFS on BRCA wild-type patients, and (D) OS on BRCA wild-type patients. HRD, homologous recombination deficiency; nLST, normalized large-scale state transition; OS, overall survival; PFS, progression-free survival.
非 KM Figure